RegenHealth Physicians
Regenerate. Repair. Restore.
New York, NY, United States
A regenerative and longevity medical practice in New York that helps patients optimize their health and wellness using modalities like Stem Cells, Exosomes, MUSE cells, peptides, medical weight loss, and IV nutritional therapy.
How We Help
Leadership
Problem Statement
Millions of Americans, 10,000 turning 65 daily, face debilitating joint pain and age-related decline, often after conventional treatments like knee replacement leave 20-30% still in pain. They're actively seeking alternatives to the opioid crisis, but current options frequently lack rigorous diagnostics, in-person labs, imaging, and comprehensive, physician-led care.
Core Technology
Advanced biologics including umbilical cord-derived Mesenchymal Stem Cells (UC-MSCs) with 97-99% viability, Exosome therapy, Peptide therapy, and proprietary Multilineage-differentiating Stress-Enduring (MUSE) cells. This is complemented by Praevorium, a proprietary data intelligence platform (in development with Auglabs) connecting clinical, biomarker, and wearable data.
Key Differentiators
Physician-led governance (not investor-owned or mid-level focused), use of high-viability allogenic UC-MSCs (97-99%) and rare MUSE cells (unlike competitors using PRP or autologous cells), a multi-vertical approach across five clinical areas (not single-specialty), proprietary Praevorium data intelligence platform for optimizing protocols, and a recurring revenue model focused on long-term prevention rather than one-time treatments. They also emphasize diagnostics-backed care with proprietary labs, imaging, and structured workups.
Clinical Focus
Longevity, Joint & Pain, Hair Restoration, Aesthetics, Sexual Health
Target Customers
Consumers aged 40+, including 30M+ Americans with osteoarthritis and the 10,000 turning 65 daily, who are actively seeking alternatives to surgery and opioids and are willing to pay cash for premium, physician-led regenerative health solutions.
Product Stage
GA
Company Info
- Business Model
- Corporate-owned clinics transitioning to a franchise model.
Disease Areas
Technologies
Clinical & IP
Clinical Validation
While general market acceptance for UC-MSC, PRP, and exosome protocols is growing, and their cell sourcing comes from FDA-regulated banks with cGMP compliance, specific clinical trials or FDA approval status for their integrated protocols are not mentioned in the deck.
Only accessible to MedStartr community members.
Join nowWhat do you think of RegenHealth Physicians?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.